Detect
cancer
Our mission is to:
Detect cancer early and increase survival rates.
Read more about our partners ->
Our Partners
01
GreinDX AS is developing a ground-breaking liquid biopsy platform to rapidly capture, identify and analyse single circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating tumor antigens (CTA), and extracellular vesicles (EV), all from one and the same blood sample. Such timely and accurate multi-biomarker information will become a cornerstone for future personalized cancer care.
We are located in Oslo Science Park and have a wide international network of scientific and technology resources. We have partnered with clinical R&D groups at Oslo University Hospital for early-stage validation, and with SINTEF MiNaLab for the development of microstructures and fluidic components of our device.
The Company
02
The problem: Scientists have during decades searched for evidence of cancer in a person’s bloodstream. The ability to isolate and study viable CTCs as well as ctDNA, CTA and EV in blood and other body fluids is expected to become a critical factor in future diagnostic, prognostic and personalized therapeutic cancer programs. However, current solutions are single-biomarker focused, cumbersome, time consuming and expensive.
Our Solution: GreinDx AS is developing a first of its kind, proprietary, and comprehensive bench-top system that can capture and study viable CTCs, ctDNA, CTA and EVs from a single blood sample or other body fluids. Our core technology is based on a proprietary porous silicon surface characterized by ordered structure, uniform porosity, and high surface area that are the ideal attributes for fluid separation as well as even distribution and storing of its constituents. We are developing a disruptive liquid biopsy platform that will be far more comprehensive, more precise, faster and come at a much lower price than current products.
The Problem and Our Solution
03
"GreinDX is developing a first of its kind, proprietary, comprehensive bench-top system that can capture and study viable CTCs, ctDNA, EVs and CTA from a single blood sample or from other body fluids"
Our Technology: GreinDX has solved a fundamental problem in fluid dynamics by developing a porous surface with properties that allow even distribution of a fluid and its constituents. This surface holds great promise for liquid biopsies and for a wide range of other application areas within both biology and chemistry.
Our novel liquid biopsy platform will be far more comprehensive, more precise, faster, and come at a much lower price than current products.
Liquid Biopsies in Cancer - a future standard clinical tool
While biopsies of tumors are currently considered the gold standard practice, they are invasive procedures that typically require surgery or needles. Often there’s insufficient tissue to analyze, or a tumor is precariously located, making a biopsy unsafe. Tissue biopsies can detect the presence of cancer, but they are inadequate for early detection, monitoring patients for relapse, and/or identifying the need for alternative treatments.
Scientists have during the last decade developed liquid biopsy tests that search for evidence of cancer in a person’s bloodstream. The ability to isolate and study circulating tumor cells (CTC) as well as circulating tumor DNA (ctDNA), extracellular vesicles (EVs) and circulating tumor antigens (CTA) in blood and other body fluids is expected to become a critical factor in future diagnostic, prognostic and personalized therapeutic cancer programs – which holds for the major solid tumor cancers as well as for leukemia.
Liquid Biopsies in Cancer - a future standard clinical tool
04
Our Partners
01
Read more about our partners ->
The Company
02
GreinDX AS is developing a ground-breaking liquid biopsy platform to rapidly capture, identify and analyse single circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating tumor antigens (CTA), and extracellular vesicles (EV), all from one and the same blood sample. Such timely and accurate multi-biomarker information will become a cornerstone for future personalized cancer care.
We are located in Oslo Science Park and have a wide international network of scientific and technology resources. We have partnered with clinical R&D groups at Oslo University Hospital for early-stage validation, and with SINTEF MiNaLab for the development of microstructures and fluidic components of our device.
Liquid Biopsies in Cancer - a future standard clinical tool
04
Our Technology: GreinDX has solved a fundamental problem in fluid dynamics by developing a porous surface with properties that allow even distribution of a fluid and its constituents. This surface holds great promise for liquid biopsies and for a wide range of other application areas within both biology and chemistry.
Our novel liquid biopsy platform will be far more comprehensive, more precise, faster, and come at a much lower price than current products.
Liquid Biopsies in Cancer - a future standard clinical tool
While biopsies of tumors are currently considered the gold standard practice, they are invasive procedures that typically require surgery or needles. Often there’s insufficient tissue to analyze, or a tumor is precariously located, making a biopsy unsafe. Tissue biopsies can detect the presence of cancer, but they are inadequate for early detection, monitoring patients for relapse, and/or identifying the need for alternative treatments.
Scientists have during the last decade developed liquid biopsy tests that search for evidence of cancer in a person’s bloodstream. The ability to isolate and study circulating tumor cells (CTC) as well as circulating tumor DNA (ctDNA), extracellular vesicles (EVs) and circulating tumor antigens (CTA) in blood and other body fluids is expected to become a critical factor in future diagnostic, prognostic and personalized therapeutic cancer programs – which holds for the major solid tumor cancers as well as for leukemia.
It’s time to admit that genes are not the blueprint for life
Phillip Ball, Nature Book Review, 5. February 2024
Team
Board of Directors
Scientific Advisory Board
The People
Welcome to our dedicated team at GreinDX. We are a group of passionate entrepreneurs, researchers, and clinicians, all committed to advancing cancer research and patient care. Each of us brings unique expertise and a shared determination to make a difference in the fight against cancer. We work together, driven by compassion and a relentless pursuit of knowledge and technology that can improve outcomes for patients and their families. Meet the people who are devoted to making progress, one step at a time.
For both preventive and precision medicine, we are seeing increasing interest in the use of liquid biopsies in the oncology space. However, there is, to our knowledge, no system currently available that allows identification, capture, isolation, and cultivating of circulating tumor cells (CTC) and other key cancer biomarkers in a single product. We are intrigued by the comprehensive approach that GreinDX is taking to address this challenge and are enthusiastic about the prospect of this “all in one” solution.
Mark J. Powers, Ph.D
Vice President R&D
Cell Biology, Cell Culture and Cell Therapy, Thermo Fisher Scientific
Our trusted partners, including SINTEF MiNaLab, Oslo University Hospital, and The European Liquid Biopsy Society, collaborate with us to advance groundbreaking cancer research and innovation.
Our partners
Prof. Vessela Kristensen
Department of Medical Genetics & Development
Oslo University Hospital
Dr. Geir Uri Jensen
Senior Scientist
SINTEF, MiNaLab
Petter Arlhed
Advisor Product
CEO & Founder Yallow
Did you know that
It is estimated that if cancer is found at an earlier stage, there is a 3−10 times higher survival rate.
CTCs, ctDNA, exosomes and CTAs from blood represent a window into the cancer that can guide clinical practice through all stages of the disease.
CTCs and exosomes are heterogenous and understanding of their role(s) is increasing every year.
Our bodies are made up of more than 30 trillion cells. Cancer cells are cells that divide relentlessly, forming solid tumors or flooding the blood with abnormal cells.
It can take up to 20 years from a damage cell to divide and grow and form a tumor large enough to cause symptoms.
SINTEF MiNaLab
Sintef MiNaLab has a complete Si processing line for 150mm wafers with state-of-the-art production equipment. The lab is ISO 9001-2015, ISO 14001-2015 and OHSAS 18001:2007 certified and belongs to the SINTEF ICT department Microsystems and Nanotechnology. Both Norwegian and international industry uses SINTEF MiNaLab for production of key components.
Oslo University Hospital.
Prof Vessela Kristensen`s group is working on different projects related to how genetic variation affects the occurrence of somatic alterations, gene expression patterns, and genome-wide copy number alterations in human breast and ovarian tumors.
Understanding inherited genetic variability and how it affects crucial biological pathways is likely to lead to new successful prevention and treatment strategies.
The European Liquid Biopsy Society (ELBS):
The ELBS pursues a holistic approach to tackling the challenges of clinical implementation in the liquid biopsy field. The network incorporates key players from academia, clinic, industry, and national government agencies to move this promising field forward collectively.
Currently the focus of the ELBS is cancer; however, we are open to including additional liquid biopsy research fields in the future (e.g. cardiovascular or inflammatory diseases).
The ELBS represents a precompetitive arena for industry partners to test and refine their technologies, assays and pipelines through the feedback of top researchers in the field.
Circulating tumor DNA (ctDNA)
is found in the bloodstream and refers to DNA that is fragmented from the cancerous cells and tumors.
Extracellular vesicles (EVs)
are lipid bilayer-delimited particles that are naturally released from almost all types of cell and, unlike a cell, cannot replicate.
Liquid Biopsies in Cancer FAQ
Circulating tumor cells (CTC)
are cells that have shed into the vasculature or lymphatics from a primary tumor and is carried around the body in the blood circulation.
Circulating tumor antigen (CTA)
are multifunctional protein groups with specific expression patterns in normal embryonic and adult cells and various types of cancer cells.
Comments from EIC Pathfinder evaluators
The (GreinDX) project aims to revolutionize liquid biopsy analysis by developing a compact, high-throughput, precision analytical device. This is, in my view, a radically new approach, especially concerning the high-throughput sample handling proposed. The vision also incorporates many novel ideas (such as open microfluidics, advanced RF sensors, peptide-based surfaces, etc., recently started to be explored), which can impact bioanalytics in the long term. These range from advanced sample handling to novel biomarker and live cell analysis. However, the physics behind these are not all entirely new; many are based on well-known basic principles, but lack technological exploitation. In my opinion, the advancement mainly lies in the clever combination of diverse technological solutions. The health sector would definitely benefit from the developments in the long term. Diverse solutions developed in the framework of this project would initiate new directions in other sample screening fields, too.”
The (GreinDX) consortium aims to examine the presence and concentration of a range of components within complex liquid samples to analyze cancer samples holds exceptional promise. While multiomic analysis of sample is today typically happening through combining data coming from multiple sources, the idea to combine multiple detection techniques in one well is visionary.”
The (GreinDX) proposal demonstrates a clear radical vision of new technology towards which the project will contribute in the long-term perspective for the way how complex liquid samples are analyzed by planning to develop a device for separating their components into uniform droplets and provide their simultaneous detection and quantification at high speed and low detection limit. This convincingly revolutionizes the nowadays available solutions for understanding the biophysical characteristics, the signatures of cells and of small components of a liquid sample.”